Cellvation
Clinical-stage biopharmaceutical company developing cellular therapeutics and supporting technologies to treat severe traumatic brain injury (TBI). Programs include autologous bone marrow-derived cell therapy clinical development and a mechanotransduction-based bioreactor to enhance anti-inflammatory properties of marrow-derived cells. Activities include preclinical in vivo studies, Phase 1/2 clinical trials, regulatory interactions and academic licensing/partnerships.
Industries
Nr. of Employees
small (1-50)
Cellvation
2 Gansevoort Street, 9th Floor, New York, NY 10014
Products
Autologous bone marrow-derived mononuclear cell therapy for severe TBI
Clinical-stage autologous bone marrow mononuclear cell product developed for intravenous administration to adults and children with severe traumatic brain injury; advanced through Phase 1 and Phase 2 studies.
Bioreactor for mechanotransductive conditioning of bone marrow-derived cells
Device and process to expose bone marrow-derived adherent cells to controlled shear stress to upregulate anti-inflammatory gene programs and enhance therapeutic potency without genetic modification; prototyped for human-scale dose production.
Autologous bone marrow-derived mononuclear cell therapy for severe TBI
Clinical-stage autologous bone marrow mononuclear cell product developed for intravenous administration to adults and children with severe traumatic brain injury; advanced through Phase 1 and Phase 2 studies.
Bioreactor for mechanotransductive conditioning of bone marrow-derived cells
Device and process to expose bone marrow-derived adherent cells to controlled shear stress to upregulate anti-inflammatory gene programs and enhance therapeutic potency without genetic modification; prototyped for human-scale dose production.
Services
Engagement with academic groups and industry partners to license, co-develop or co-fund cellular therapy programs for TBI.
Engagement with academic groups and industry partners to license, co-develop or co-fund cellular therapy programs for TBI.
Expertise Areas
- Cell therapy development
- Traumatic brain injury therapeutics
- Clinical trial management for autologous cell therapies
- Mechanotransduction-based cell conditioning
Key Technologies
- Autologous bone marrow-derived cell therapy
- Bioreactor mechanotransduction (wall shear stress) conditioning
- Mesenchymal stromal cell immunomodulation
- IV cell delivery
News & Updates
Publication reporting Phase 1 clinical study data indicating safety and possible efficacy signals of autologous bone marrow-derived cell therapy in adults with severe TBI, including mitigation of inflammatory biomarkers and CNS structural preservation.
Regulatory designation granted by the U.S. FDA to facilitate expedited development and review of the clinical-stage autologous bone marrow-derived cell therapy for treatment of TBI.
Approximately $10 million in grant funding from the National Institutes of Health and the Department of Defense to support two Phase 2 clinical studies in pediatric and adult severe TBI.
Publication reporting Phase 1 clinical study data indicating safety and possible efficacy signals of autologous bone marrow-derived cell therapy in adults with severe TBI, including mitigation of inflammatory biomarkers and CNS structural preservation.
Regulatory designation granted by the U.S. FDA to facilitate expedited development and review of the clinical-stage autologous bone marrow-derived cell therapy for treatment of TBI.
Approximately $10 million in grant funding from the National Institutes of Health and the Department of Defense to support two Phase 2 clinical studies in pediatric and adult severe TBI.